Completed OBSERVATIONAL NCT01284608

Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) (UROCOR)

Sponsor: AstraZeneca

Updated 7 times since 2017 Last updated: Dec 21, 2012 Started: Mar 31, 2011 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01284608, this observational or N/A phase trial focuses on Prostatic Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albacete, Spain , Alcalá de Henares, Spain , Antequera, Spain , Aranda de Duero, Spain , Barakaldo, Spain , Barcelona, Spain , Bilbao, Spain , Calatayud, Spain , Coslada, Spain , Córdoba, Spain and 23 more locations